VELCADE

In the US, VELCADE (bortezomib systemic) is a member of the drug class proteasome inhibitors and is used to treat Lymphoma, Mantle Cell Lymphoma and Multiple Myeloma.

US matches:

UK matches:

Ingredient matches for VELCADE

Bortezomib

Bortezomib is reported as an ingredient of VELCADE in the following countries:

  • Antigua & Barbuda
  • Argentina
  • Aruba
  • Australia
  • Austria
  • Bahamas
  • Barbados
  • Belgium
  • Bermuda
  • Brazil
  • Canada
  • Cayman Islands
  • Chile
  • China
  • Colombia
  • Croatia (Hrvatska)
  • Czech Republic
  • Denmark
  • Ecuador
  • Finland
  • France
  • Georgia
  • Germany
  • Greece
  • Grenada
  • Guyana
  • Hong Kong
  • Hungary
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Latvia
  • Lithuania
  • Luxembourg
  • Malaysia
  • Mexico
  • Netherlands
  • New Zealand
  • Norway
  • Oman
  • Philippines
  • Poland
  • Romania
  • Russian Federation
  • Saint Lucia
  • Saint Vincent & The Grenadines
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • South Korea
  • Suriname
  • Switzerland
  • Thailand
  • Trinidad & Tobago
  • Turkey
  • United Kingdom
  • United States
  • Venezuela
  • Vietnam

International Drug Name Search

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web4)